IN RECENT YEARS there have been several reports of scission products appearing in urine as a result of folate degradation. p-Acetamidobenzoate and p-acetamidobenzoyl-L-glutamate (Murphy et al., 1976) have been identified as catabolites of 3H folate tracers; pterin and isoxanthopterin have been detected after folic acid administration (Fukushima & Shiota, 1972; Krumdieck et al., 1978) and reported an unidentified pteridine as a metabolite of 3H-and 14C-folic acid.
A number of studies suggest that the pattern of folate coenzymes in malignant or normal rapidly dividing tissues is different from that of resting tissues (Sotobayashi et al., 1966; Barbiroli et al., 1975) and Stea et al. (1978) have claimed that tumour cells in culture produce 6-hydroxymethylpterin as a specific catabolite of folic acid. Folate metabolism in vivo is known to be affected by the presence of a tumour; preliminary studies suggest that the catabolism of folate may be depressed Saleh et al., 1980) . Methotrexate (MTX) is a folate antagonist which is used in cancer chemotherapy. It is a potent inhibitor of dihydrofolate reductase (EC.1.5.1.3, DHFR) (Bertino et al., 1964) and is presumed to act by inhibiting this enzyme. However, the in vivo situation is complex, and a number of interacting mechanisms may be involved in MTX cytotoxicity (Goldman, 1977) . The drug also inhibits other folate-dependent enzymes (e.g. thymidylate synthetase (EC.2.1.1.45) (Borsa & Whitmore, 1969) albeit at higher concentration) and acts on dihydropteridine reductase (EC.1.6.99.10) (Craine et al., 1972) and Barford et al., 1980) have presented evidence that DHFR is not the sole target of MTX methotrexate in vivo. The major tissue folate derivatives are polyglutamyl conjugates (Shin et al., 1972 (Shin et al., , 1974 Connor & Blair, 1980 ) and it appears likely that these derivatives function as coenzymes (Rowe, 1978) . Previous studies have largely been concerned with the effect of MTX on the metabolism of radiolabelled folate monoglutamates. Administration of MTX, with or before folic acid, causes excretion of large amounts of unchanged folic acid, with little or no radio-label incorporated into the folate pool (Barford et al., 1980) . Effects on the normal tissue folates are therefore difficult to establish. The present study compares the metabolism of a mixture of 2-14C-folic acid and 3',5',7,9-3H-folic acid in normal rats, in rats treated with MTX and in tumour-bearing rats, the experiments involving MTX being designed to study its effect on folate polyglutamate metabolism, particularly their breakdown.
MATERIALS AND METHODS
Experimental design.-Three groups of male syngeneic WAB/Not rats were used. Each group consisted of 15 rats.
Group 1: Control rats (160-240 g body wt). GroupII: Rats bearing Mc103B sarcoma (260-320 g).
Group ) treated with MTX.
All rats received an oral dose of a mixture of 2-14C-and 3',5',7,9-3H-folic acid (100 pg/kg).
Animals were then housed in metabolism cages (Jencons Metabowls, Jencons Scientific Ltd, Hemel Hempstead, Herts) designed for the separate collection of urine and faeces. Eight hours after the administration of labelled folic acid, 5 animals from each group were killed by cervical dislocation and the remaining animals of Group III were given an oral dose of MTX (100 mg/kg). Synthesis of folate polyglutamates in the tissues from labelled folic acid is complete by this time (Bates et al., 1980) . At 24 h a further 5 animals from each group were killed and the remainder of Group III received a second dose of MTX (100 mg/kg (Pimm et al., 1980) . For this experiment the sarcoma was implanted s.c. on the right flank and allowed to grow for 4 weeks.
Collection of urine and faeces.-Urine from 5 rats for each interval was collected into flasks containing 10 ml of 0-05M sodium phosphate buffer (pH 7.0) containing 2%°,h (w/v) sodium ascorbate and 5 mg% (w/v) dithiothreitol. To prevent light degradation of folates the flasks were surrounded by aluminium foil. Collection flasks of urine and faeces were changed 8, 24 and 48 h after administration of labelled folic acid.
Preparation of liver and tumour extracts. Hot extracts of livers and tumours were prepared as described by Barford et al. (1977) .
Determination of radioactivity.-Urine samples and column effluents were counted as described in Connor et al. (1979) . Faeces and tissue samples were freeze-dried and ground to give a homogeneous powder; 100mg samples were used to estimate total radioactivity, as described by .
Column chromatography.-Sephadex G15 gel filtration and DEAE-cellulose chromatography (using linear gradients of 0-1 2M NaCl in 0-05M sodium phosphate buffer, pH 7 0) were performed as described by Barford et al. (1977) .
Paper chromatography was performed as described by Connor et al. (1979) .
Chemical8.-All chemicals used were of Analar grade or its equivalent. 2-14C-folic acid (sp. radioact. 58 mCi/mmol) and 3',5',7,9-3H-folic acid (sp. radioact. 500 mCi/mmol) were obtained from the Radiochemical Centre, Amersham, Bucks. p-Acetamidobenzoyl-Lglutamate was prepared as described in Baker et al. (1964) , 10-formylfolate was synthesized from folic acid (Blakley, 1959) , 5,10-methylene-tetrahydrofolate was prepared by Dr R. Nayyir Mazhir as described by Osborn et al. (1960) , pterin-6-aldehyde- (Waller et al., 1950 ) and pterin-6-carboxylic acid (Zakrewski et al., 1970) were prepared by Dr M. Connor in this department. Table I summarizes the recovery of 3H and 14C radioactivity in the urine and faeces of the 3 groups of animals. More 3H than 14C was excreted in the urine of all animals, and an excess of 14C over 3H Group ITI 6-1+09 3-8+05 30+0-5 2-1+0-3 13-9 + 1-3 11-4 + 0-8 11-0+0-9 22-1+1-9 3-4 +290 9-7 + 5-2 5-3 + 1-8 10-2 + 3 9 30+03 2-1+0-2 12-+0.1
RESULTS
10+0-2 0-7+0-4 0-8+0-5 was present in the faeces. No significant differences were observed in 0-8 h urinary radioactivity between control animals (taken as Group 1+111) and tumourbearing animals (Group II). In the later intervals the tumour-bearing rats excreted significantly less radioactivity in urine than control rats (Group I) (P < 002 for Table II 
Effect of a tumour
Tumour-bearing rats excreted less radioactivity in both the urine and faeces. Qualitatively this is due to a lowered excretion of most metabolites in the urine. Although excretion of unchanged folic acid was higher than normal, overall excretion of folates was reduced. This is probably due to uptake of folate and formation of polyglutamates by a large tumour mass. Similar observations have been reported for human subjects suffering from malignancies (Saleh et al., 1980) . Catabolism of folate was also decreased in the tumour-bearing rats. The catabolites appearing after the initial 8 h period arise principally from the breakdown of folate polyglutamates, since there was no evidence of folate monoglutamates in the tissue extracts. p-Acetamidobenzoyl-Lglutamate is derived by breakdown of the tissue polyglutamates, whereas p-acetamidobenzoate is the catabolite of the monoglutamate pool (Connor, 1979) . The levels of p-acetamidobenzoyl-L-glutamate can therefore be used as a measure of the breakdown of tissue polyglutamate. Excretion of this compound in the urine is decreased in the tumour-bearing animals. This observation is particularly striking if the increased radioactivity in the tissues of the tumour-bearing animals is taken into account. The larger amounts of radiolabelled polyglutamates would be expected to lead tion of radio-labe L-glutamate, if ti unaltered, wher4 activity found in excreted as p-a mate by the t compared to 6*9' VII). to an increased produc-ing binding proteins, and/or to the inhibiblled p-acetamidobenzoyl-tion of uptake of folates into cells (Goldhe catabolic rate remained man, 1971). MTX also increased the eas 4.4% of the radio-catabolism of folate, which is seen as an the tissues after 8 h was increase in urinary catabolites, particu-,cetamidobenzoyl-L-gluta-larly p-acetamidobenzoyl-L-glutamate tumour-bearing animals, (28% of the activity retained in the tissues >% for the controls (Table after hyde, p-aminobenzoyl-L-glutamate, dihydroxanthopterin and 7,8-dihydropterin-21-1 5 9 28-0 6-carboxaldehyde (Chippel & Scrimgeour, 1970) . The dihydro derivatives are likely the folate molecule most to oxidize further, giving xanthopterin ds by oxidative scission and pterin-6-carboxylic acid respectively. ate derivative produced Thus inhibition of dihydrofolate reductase, mal metabolic pathways. leading to increased breakdown of die known to exhibit more hydrofolate derivatives, can account for a rns in their cytosol, which proportion of the increase in p-acetamidoncreased lactate/pyruvate benzoyl-L-glutamate excretion and the 7t al., 1971; Williamson appearance of xanthopterin, pterin-6-Excessive production of carboxylic acid, 3H20 and folic acid in nour can also lead to in-the urine of rats treated with MTX, but in the blood, which thus cannot explain the formation of pterin.
tissues. Also, hypoxia is Neither is pterin produced by the metabolid animal and human lism in vivo of pterin-6-carboxylic acid lecreased catabolism of (Pheasant & Pearce, 1981) .
3ence of a tumour may be However, oxidation of tetrahydrofolate tbilization of the labile via quinonoid dihydrofolate gives pterin 3 by the more reducing and xanthopterin as the final products iling. (Blair and Pearson, 1974) . This suggests that tetrahydrofolate derivatives may be xate involved in the catabolic process. Thus the -ation of MTX increased fragments found in urine after MTX cretion of radioactivity. administration are only consistent with Keretion of folic acid and the breakdown of both tetrahydrofolate drofolate immediately and dihydrofolate polyglutamates in the nistration could be due to tissues. the folates from circulatDihydropteridine reductase has been shown to use quinonoid dihydrofolate as a substrate (Lind, 1972) and Pollock & Kaufman (1978) have suggested that this enzyme may act in the maintenance of the reduced folates. MTX inhibits dihydropteridine reductase with a K1 of 3-8 x 10-5M (Craine et al., 1972) and this could cause increased folate breakdown from tetrahydrofolate via quinonoid dihydrofolate. The effect of MTX on serum biopterin derivatives (Leeming et al., 1976) suggests that such inhibition of dihydropteridine reductase occurs in vivo. The appearance of pterin in the urine after MTX administration is further evidence that dihydropteridine reductase does have a role in folate metabolism in vivo and that MTX interferes with this role.
Recently 5,1 0-methylenetetrahydrofolate reductase (EC. 1.1.1.171) has also been shown to have dihydropteridine reductase activity, and to reduce quinonoid dihydrofolate to tetrahydrofolate (Mat-thews & Kaufman, 1980) . This enzyme is weakly inhibited by MTX (Magnum etal., 1979) .
Thus these studies on the catabolism of the folate polyglutamates suggest that dihydrofolate reductase is not the sole enzyme affected by MTX in vivo. Other possible target enzymes include dihydropteridine reductase and 5,10-methylenetetrahydrofolate reductase. The design of anti-folate drugs to maximize their effect on these enzymes could lead to a more effective chemotherapeutic agent which depletes the cell of folate by increasing breakdown. This could be particularly useful since the catabolic process seems to be decreased in a tumour.
